TG Therapeutics (NASDAQ:TGTX) and Myokardia (NASDAQ:MYOK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Risk & Volatility
TG Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Myokardia has a beta of 3.42, meaning that its share price is 242% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for TG Therapeutics and Myokardia, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TG Therapeutics currently has a consensus price target of $21.50, indicating a potential upside of 326.59%. Myokardia has a consensus price target of $78.00, indicating a potential upside of 25.66%. Given TG Therapeutics’ higher probable upside, research analysts plainly believe TG Therapeutics is more favorable than Myokardia.
Earnings and Valuation
This table compares TG Therapeutics and Myokardia’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TG Therapeutics||$150,000.00||2,785.44||-$118.47 million||($1.91)||-2.64|
|Myokardia||$22.50 million||111.09||-$45.95 million||($1.40)||-44.34|
Myokardia has higher revenue and earnings than TG Therapeutics. Myokardia is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares TG Therapeutics and Myokardia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
49.8% of TG Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Myokardia shares are held by institutional investors. 15.1% of TG Therapeutics shares are held by company insiders. Comparatively, 33.4% of Myokardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Myokardia beats TG Therapeutics on 10 of the 13 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications; and a collaboration with 23andMe, Inc. to advance research for patients with hypertrophic cardiomyopathy. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.